Search our Database of Scientific Publications and Authors

I’m looking for a

    11029 results match your criteria Cutaneous T-Cell Lymphoma

    1 OF 221

    Two cases of hydroa vacciniforme-like lymphoproliferative disease controlled by anti-inflammatory agents.
    Photodermatol Photoimmunol Photomed 2017 May 24. Epub 2017 May 24.
    Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
    Hydroa vacciniforme-like lymphoproliferative disease (HVLL) was first described as the coexistence of hydroa vacciniforme and malignant lymphoma in 1986. It was renamed in the 2008 World Health Organization classification system as one of the Epstein-Barr virus (EBV)-associated lymphoproliferative diseases (LPDs) of childhood. HVLL has T cell monoclonality and is considered a rare EBV(+) cutaneous T cell lymphoproliferative disease. Read More

    Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
    Curr Hematol Malig Rep 2017 May 24. Epub 2017 May 24.
    Penn Cutaneous Lymphoma Program, Department of Dermatology, Perelman Center for Advanced Medicine, Perelman School of Medicine at the University of Pennsylvania, 1st Floor South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
    Purpose Of Review: Diagnosis and management of mycosis fungoides and Sézary syndrome (MF/SS) require accurate clinicopathological correlation and a multidisciplinary approach. We reviewed major advances in the field regarding diagnostic and prognostic tools as well as skin-directed therapies (SDTs) and systemic agents for MF/SS published in the past 2 years.

    Recent Findings: Improved technology (T-cell receptor high-throughput sequencing) and increased multicenter collaboration (Cutaneous Lymphoma International Consortium) have led to diagnostic/prognostic advances. Read More

    NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Oncotarget 2017 May 7. Epub 2017 May 7.
    German Cancer Research Center, 69120 Heidelberg, Germany.
    Therapy of cutaneous T cell lymphoma (CTCL) is complicated by a distinct resistance of the malignant T cells towards apoptosis that can be caused by NRAS mutations in late-stage patients. These mutations correlate with decreased overall survival, but sensitize the respective CTCL cells towards MEK-inhibition-induced apoptosis which represents a promising novel therapeutic target in CTCL. Here, we show that the multi-kinase inhibitor Sorafenib induces apoptosis in NRAS-mutated CTCL cells. Read More

    Research Techniques Made Simple: High-Throughput Sequencing of the T-Cell Receptor.
    J Invest Dermatol 2017 Jun;137(6):e131-e138
    Academic Medical Center, Department of Dermatology, University of Amsterdam, Amsterdam, The Netherlands.
    High-throughput sequencing (HTS) of the T-cell receptor (TCR) is a rapidly advancing technique that allows sensitive and accurate identification and quantification of every distinct T-cell clone present within any biological sample. The relative frequency of each individual clone within the full T-cell repertoire can also be studied. HTS is essential to expand our knowledge on the diversity of the TCR repertoire in homeostasis or under pathologic conditions, as well as to understand the kinetics of antigen-specific T-cell responses that lead to protective immunity (i. Read More

    Harefuah 2016 Oct;155(10):613-615
    The Department of Dermatology, Haemek Medical Center, Afula, Israel.
    Introduction: Unilesional mycosis fungoides is a rare cutaneous T cell lymphoma that warrants either radiation therapy or surgical excision. Benign characteristics result in misdiagnosis, delayed tissue biopsy and subsequently delayed provision of adequate treatment. A young patient presented with a history of 18 months of eczematous benign - appearing single lesion restricted to her index finger. Read More

    Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
    J Dermatol Nurses Assoc 2016 May 9;8(3):180-192. Epub 2016 Jun 9.
    Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
    Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Stage IA and IB mycosis fungoides cutaneous T-cell lymphoma can be effectively controlled by skin-directed therapies such as the mechlorethamine gel approved by the Food and Drug Administration. Dermatology nurses play a key role in promoting good patient compliance through patient education about mycosis fungoides cutaneous T-cell lymphoma disease, proper administration of mechlorethamine gel, and connecting patients with patient assistance programs or other supportive services. Read More

    Regulation of the glycerol transporter, aquaporin-3, by histone deacetylase-3 and p53 in keratinocytes.
    J Invest Dermatol 2017 May 16. Epub 2017 May 16.
    Charlie Norwood VA Medical Center, Augusta, GA 30904, USA; Department of Physiology, Augusta University, Augusta, GA 30912, USA; Department of Medicine (Dermatology), Augusta University, Augusta, GA 30912, USA; Department of Oral Biology, Augusta University, Augusta, GA 30912, USA.
    Aquaporin-3 (AQP3), a water and glycerol channel, plays an important role in epidermal function, with studies demonstrating its involvement in keratinocyte proliferation, differentiation and migration and epidermal wound healing and barrier repair. Increasing speculation about the use of histone deacetylase (HDAC) inhibitors to treat skin diseases led us to investigate HDAC's role in the regulation of AQP3. The broad-spectrum HDAC inhibitor, suberolyanilide hydroxamic acid (SAHA) induced AQP3 mRNA and protein expression in a dose- and time-dependent manner in normal keratinocytes. Read More

    Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.
    Eur J Dermatol 2017 May 19. Epub 2017 May 19.
    Department of Dermatology, Saint-André Hospital CHU Bordeaux, Bordeaux, France, INSERM U1053, Bordeaux Research in Translational Oncology University Bordeaux, Bordeaux, France, French Study Group of Cutaneous Lymphoma (GFELC).
    Hypersensitivity reactions (HSR) to pegylated liposomal doxorubicin (PLD; Caelyx(®)) have been reported, and symptoms usually resolve with drug withdrawal. However, the risk of relapse of severe HSR and prevention remain poorly described. To report the management and outcome in four patients with HSR due to PLD. Read More

    Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides.
    Arch Dermatol Res 2017 May 17. Epub 2017 May 17.
    Department of Dermatology, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA.
    Folliculotropic mycosis fungoides (FMF) is a distinct variant of mycosis fungoides (MF) where atypical T-cells invade the hair follicles. The objective was to assess the clinical features, risk factors for progression, long-term outcome and response to treatment modalities in a large cohort of FMF patients. We, therefore, conducted a single-center retrospective study, reviewing 114 patients with FMF seen from 1987 to 2015 at the cutaneous T-cell lymphoma clinic of the MD Anderson Cancer Center. Read More

    Cutaneous Anaplastic Large T-Cell Lymphoma with Invasion of the Central Nervous System: A Case Report.
    Brain Tumor Res Treat 2017 Apr 30;5(1):45-48. Epub 2017 Apr 30.
    Department of Neurosurgery, Konyang University Hospital, Daejeon, Korea.
    Anaplastic large T-cell lymphoma (ALCL) encompasses different clinical entities that can be aggressive or localized. Scalp anaplastic lymphoma kinase (ALK)-negative ALCL is considered a localized lymphoma, and usually extends to the regional lymph nodes; intracranial invasion is rare. A 74-year-old woman was diagnosed with scalp ALK-negative ALCL, but did not exhibit invasion of the lymph nodes. Read More

    Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.
    AIDS 2017 May 16. Epub 2017 May 16.
    aThe Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia bDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark cDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia dVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon National Primate Research Center, Oregon, USA eThe Westmead Institute, University of Sydney, Westmead, NSW, 2145, Australia fDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia gSir Peter MacCallum Department of Oncology, University of Melbourne and Epworth Healthcare, East Melbourne, Australia.
    Objective: To study the effects of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy (ART) with Sezary syndrome, a rare malignancy of CD4+ T-cells DESIGN:: Case report.

    Methods: Blood was collected 30 and 18 months prior to presentation with Sezary syndrome, at the time of presentation and during alemtuzumab. T-cell subsets in malignant (CD7-CD26-TCR-VBeta2+) and non-malignant cells were quantified by flow cytometry. Read More

    Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy.
    Case Rep Oncol 2017 Jan-Apr;10(1):328-332. Epub 2017 Apr 6.
    Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL). Since it is difficult to distinguish AI from ichthyosiform mycosis fungoides, to select the treatment for CTCL with ichthyosis-like appearance and to evaluate its efficacy is sometimes challenging. In this report, we describe a case of primary cutaneous peripheral T-cell lymphoma not otherwise specified presenting AI successfully treated with oral bexarotene. Read More

    Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man.
    Case Rep Dermatol 2017 Jan-Apr;9(1):103-107. Epub 2017 Apr 7.
    aDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
    The development of both a T- and B-cell lymphoproliferative disorder in one patient is an unlikely coincidence due to the low prevalence of each malignancy. We report a 65-year-old man with a previously documented history of B hairy cell leukemia, who presented with a new-onset acneiform eruption of his scalp, face, trunk, back, and extremities. Routine pathology of the skin lesions with immunohistochemical stains and molecular studies were consistent with a folliculotropic mycosis fungoides. Read More

    Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Department of Dermatology, University Hospitals Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW.
    Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), accounting for 55% cases(1) . Although incurable, it most often presents in early-stage with a good prognosis. The primary aim is to minimise symptoms and maximise quality of life. Read More

    Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    J Cutan Pathol 2017 May 12. Epub 2017 May 12.
    University of Iowa Hospitals and Clinics, Departments of Dermatology and Pathology, 200 Hawkins Drive, Iowa City, IA, 52242.
    CD8-positive, CD30-positive cutaneous lymphoproliferative disorders comprise a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma, and cutaneous peripheral T-cell lymphoma. These entities share overlapping clinical, histopathologic, and immunophenotypic features, presenting both a clinical and pathological diagnostic challenge. Presented here is a 73-year-old man with a disseminated, indolent CD30+, CD8+ cutaneous lymphoproliferative disorder with overlapping clinical and histopathological features of both mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, as well as features of lymphomatoid papulosis. Read More

    Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Cancer 2017 May 10. Epub 2017 May 10.
    Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada.
    Background: Previous reports of geographic clustering of cutaneous T-cell lymphoma (CTCL) in Texas, Pittsburgh, and Sweden as well as the occurrence of CTCL in married couples and family members raise a possibility of the existence of an external and potentially preventable trigger(s) for this rare skin cancer.

    Methods: The authors studied CTCL incidence and mortality in Canada using 3 distinct population-based cancer databases. Data on patients' sex, age at the time of diagnosis, subtype of CTCL malignancy, reporting province, city, and postal code were analyzed. Read More

    Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Oncotarget 2017 Apr 24. Epub 2017 Apr 24.
    Clinic for Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.
    Sézary syndrome (SS) is an aggressive, leukemic cutaneous T-cell lymphoma variant. Molecular pathogenesis of SS is still unclear despite many studies on genetic alterations, gene expression and epigenetic regulations. Through whole genome and transcriptome next generation sequencing nine Sézary syndrome patients were analyzed in terms of copy number variations and rearrangements affecting gene expression. Read More

    Cutaneous Lymphomas with Cytotoxic Phenotype.
    Surg Pathol Clin 2017 Jun 28;10(2):409-427. Epub 2017 Mar 28.
    Dermatopathology Laboratory, St John's Institute of Dermatology, St Thomas' Hospital, South Wing, Staircase C, Westminster Bridge Road, London SE1 7EH, UK. Electronic address:
    Primary cutaneous cytotoxic lymphomas are T-cell or natural killer-cell lymphomas that express 1 or more cytotoxic markers. These neoplasms constitute a spectrum of diseases. In this review, an overview of clinical, morphologic, and phenotypical features of each subtype is provided. Read More

    Primary cutaneous extranodal natural killer/T-cell lymphoma presenting as bilateral erythematous patches on the arms.
    Indian J Dermatol Venereol Leprol 2017 Apr 27. Epub 2017 Apr 27.
    Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    Natural killer/T-cell lymphoma is a rare, Epstein-Barr virus-associated type of cytotoxic lymphoma thatpresents mainly in the nasal cavity and its vicinity. Very few cases of primary cutaneous extranodal natural killer/T-cell lymphoma have been reported till date. All the previously reported cases of primary cutaneous extranodalnatural killer/T-cell lymphoma presented as lesions resembling cellulitis, subcutaneous nodules or ulcers. Read More

    Septicemia and pneumonia due to Mycobacterium fortuitum infection in a patient with extronodal NK/T-cell lymphoma, nasal type: A case report.
    Medicine (Baltimore) 2017 May;96(18):e6800
    aDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University bDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University cDepartment of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
    Rationale: Mycobacterium fortuitum (M.fortuitum) is one of the rapidly growing nontuberculous mycobacterium (NTM) that is widespread in the environment. M. Read More

    A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
    Eur J Dermatol 2017 May 3. Epub 2017 May 3.
    Dermatologic Clinic, Department of Medical Sciences, University of Turin, Italy.
    EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs). The aim was to investigate whether maintenance treatment with lenalidomide prolonged response after debulking in patients who had not been previously treated with intravenous chemotherapy. A total of 26 centres from 10 different European countries registered 30 patients with advanced CTCL. Read More

    Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
    Int J Hematol 2017 May 2. Epub 2017 May 2.
    BMT Unit, Department of Hematology, Cebeci Hospital, School of Medicine, Ankara University, Dikimevi, 06590, Ankara, Turkey.
    Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. Read More

    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol 2017 May 1:JCO2016712083. Epub 2017 May 1.
    Camille Laurent, Nadia Amara, Georges Delsol, and Pierre Brousset, Institut Universitaire du Cancer-Oncopole de Toulouse; Centre Hospitalier Universitaire (CHU) Toulouse; Camille Laurent, Georges Delsol, and Pierre Brousset, Institut National de la Santé et de la Recherche Médicale (INSERM), U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, Laboratoire d'Excellence Toulouse Cancer; Thomas Filleron, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse, Toulouse; Marine Baron, Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier; Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, INSERM U955, Université Paris-Est, Créteil; Mylène Dandoit, Marc Maynadié, and Laurent Martin, CHU de Dijon, Dijon; Marie Parrens, Beatrice Vergier, and Antoine de Mascarel, Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux; Bettina Fabiani, AP-HP, Hôpital Saint-Antoine; Nicole Brousse and Thierry Jo Molina, AP-HP, Hôpital Necker; Josette Brière, AP-HP, Hôpital Saint Louis; Fréderic Charlotte, AP-HP, Hôpital Pitié Salpétrière; Diane Damotte, AP-HP, Hôpitaux Universitaires Paris Centre, Paris; Alexandra Traverse-Glehen and Françoise Berger, CHU Lyon-Sud; Catherine Chassagne-Clement, Centre Léon Bérard, Lyon; Marie-Christine Copin, Univ Lille, CHU Lille, Lille; Patrick Tas, CHU de Rennes, Rennes; Marie-Christine Rousselet, CHU d'Angers, Angers; Thérèse Rousset, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier; Luc Xerri, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille; Anne Moreau and Céline Bossard, Hôpital Hôtel Dieu, CHU de Nantes, Nantes; Antoine Martin, Hôpital Avicenne, Bobigny, Bobigny; Peggy Dartigues, Institut Gustave Roussy, Villejuif; Isabelle Soubeyran, Institut Bergonié, Bordeaux; Michel Peoch, CHU de Saint Etienne, Saint Etienne; Pierre Dechelotte, CHU de Clermont-Ferrand, Clermont-Ferrand; Jean-François Michiels, CHU de Nice, Nice; Flavie Arbion, CHU de Tours, Tours; Isabelle Quintin-Roué, CHU de Brest, Brest; Jean-Michel Picquenot, Centre Henri Becquerel, CHU de Rouen, Rouen; Martine Patey, CHU de Reims, Reims; Blandine Fabre, CHU de Grenoble, Grenoble; Henri Sevestre, CHU d'Amiens, Amiens; Cécile Le Naoures, CHU de Caen, Caen; Marie-Pierre Chenard-Neu, CHU de Strasbourg, Strasbourg; Claire Bastien, CHU de Nancy, Nancy; Sylvie Thiebault, CH de Mulhouse, Mulhouse; Manuela Delage, CHU de Limoges, Limoges; Gilles Salles, Hospices Civils de Lyon, CHU Lyon-Sud; Gilles Salles, INSERM1052, Centre National de la Recherche Scientifique 5286, Université Claude Bernard, Pierre Bénite, France; Tony Petrella, Pathology University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada.
    Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Read More

    Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma.
    Oncol Res Treat 2017 25;40(5):244-252. Epub 2017 Apr 25.
    Total-skin electron beam therapy (TSEBT) is one of most effective treatments that has been used for cutaneous T-cell lymphoma. Low-dose TSEBT regimens (10-12 Gy) appear to be an effective alternative to conventional-dose TSEBT (30-36 Gy), yielding short-term remission of cutaneous manifestations with minimal toxicity. TSEBT can be administered to patients any time after a diagnosis of mycosis fungoides (MF). Read More

    Forodesine in the treatment of cutaneous T-cell lymphoma.
    Expert Opin Investig Drugs 2017 Jun 5;26(6):771-775. Epub 2017 May 5.
    b Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Introduction: Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of neoplastic CD4+ T lymphocytes in the skin. Given the lack of curative treatments for CTCL, there is a significant need for new, superior therapies. Forodesine is a transition-state analogue that inhibits purine nucleoside phosphorylase. Read More

    CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides.
    Cancer Control 2017 Apr;24(2):207-212
    Hematopathology & Laboratory Medicine Program, Moffitt Cancer Center, Tampa, FL.
    A white woman aged 65 years presented with a macular, nonscaly, nonpruritic, erythematous lesion on her right breast. Test results revealed histological features similar to lichenoid dermatitis and early-phase primary cutaneous T-cell lymphoma with a subtype of mycosis fungoides (MF). Despite topical therapy with steroids, her skin disease continued to progress, so she underwent polymerase chain reaction and gene mutation testing. Read More

    ALK Expression is a Rare Finding in Mycosis Fungoides.
    Am J Dermatopathol 2017 May;39(5):342-343
    *Department of Dermatology, University of Chicago Hospital Medical Center, CA, IL; and †Department of Pathology, Southern Permanente Medical Group, LA, CA.
    Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Although indolent in its early stages, MF is more aggressive in advanced stages, particularly if large cell transformation occurs. Histologically, transformed MF is similar to primary cutaneous anaplastic large cell lymphoma (pcALCL) and nodal ALCL (nALCL). Read More

    Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation.
    Oncol Res Treat 2017 20;40(5):262-269. Epub 2017 Apr 20.
    Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and Sézary syndrome as the most common subtypes. The current treatment outcome is characterized by high rates of relapse, but survival is usually not significantly shortened in low-stage disease. This is different in tumor-stage disease or aggressive CTCL subtypes where survival is significantly reduced. Read More

    Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.
    Oncotarget 2017 Apr;8(16):26245-26255
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.
    Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with generally poor outcomes following standard therapy. Few candidate therapeutic targets have been identified to date. Retinoic acid receptor alpha (RARA) is a transcription factor that modulates cell growth and differentiation in response to retinoids. Read More

    The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment.
    J Leukoc Biol 2017 Apr 13. Epub 2017 Apr 13.
    Immunology Area, Ospedale Pediatrico Bambino Gesù, Roma, Italy
    IL-31 is a recently identified cytokine with a well-defined role in the pathogenesis of pruritus. IL-31, whose production is induced by IL-4 and IL-33, binds a heterodimeric receptor (R) composed of the exclusive IL-31RA chain and the shared oncostatin M R. Signaling through the IL-31R involves the MAPK, PI3K/AKT and Jak/STAT pathways. Read More

    Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.
    Oncoimmunology 2017 10;6(3):e1273310. Epub 2017 Feb 10.
    Department of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital , Helsinki, Finland.
    Indoleamine 2,3-deoxygenase 1 (IDO1) induces immune tolerance in the tumor microenvironment (TME) and is recognized as a potential therapeutic target. We studied the expression of both IDO1 and the related tryptophan 2,3-dioxygenase (TDO) in several different subtypes of cutaneous T-cell lymphoma (CTCL), and evaluated the kynurenine (KYN) pathway in the local TME and in patient sera. Specimens from the total of 90 CTCL patients, including mycosis fungoides (MF, n = 37), lymphomatoid papulosis (LyP, n = 36), primary cutaneous anaplastic large cell lymphoma (pcALCL, n = 4), subcutaneous panniculitis-like T-cell lymphoma (SPTCL n = 13), and 10 patients with inflammatory lichen ruber planus (LRP), were analyzed by immunohistochemistry (IHC), immunofluorescence (IF), quantitative PCR, and/or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Read More

    CD3+, CD56+, CD4-, CD8-, CD20-, CD30- Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report.
    Indian J Dermatol 2017 Mar-Apr;62(2):200-202
    Department of Skin and VD, B.J. Medical College and Civil Hospital, Ahmedabad, Gujarat, India.
    Cutaneous T-cell lymphoma (CTCL) commonly presents as mycosis fungoides or Sezary syndrome, both having CD4 positivity. A subset of CTCL which lacks CD4 surface marker is classified as cutaneous γ and δ-T-cell lymphoma (CGD-TCL). Because of its rarity and inability to study large number of patients, the impact of immunophenotype on the clinical outcome of primary CTCL in patients is limited. Read More

    New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Indian J Dermatol 2017 Mar-Apr;62(2):142-145
    Department of Dermatology, University Paris 7, Hopital Saint-Louis, Paris, France.
    Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath) is a humanized IgG1 kappa monoclonal antibody specific for CD52, an antigen expressed by most T and B lymphocytes. Read More

    Management Strategies for Mycosis Fungoides in India.
    Indian J Dermatol 2017 Mar-Apr;62(2):137-141
    Department of Dermatology, Tata Medical Centre, Kolkata, West Bengal, India.
    Mycosis fungoides is the most common primary cutaneous T-cell lymphoma. The approach to diagnosis and further follow-up is outlined. Evidence for interventions is based classically on a Tumor Node Metastasis Blood TNMB "stage-based" approach. Read More

    [Granulomatous slack skin associated with metastatic testicular seminoma].
    Ann Dermatol Venereol 2017 Apr 7. Epub 2017 Apr 7.
    Service de dermatologie, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address:
    Background: Granulomatous slack skin (GSS) is an extremely rare subtype of T-cell lymphoma, a variant of mycosis fungoides (MF). Herein, we describe the first reported case of GSS associated with metastatic testicular seminoma.

    Patients And Methods: A 28-year-old male patient presented with circumscribed erythematous loose skin masses, especially in the body folds and which had been relapsing for 4years. Read More

    Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediating Cytotoxic Activity against Tumor Cells via CD155.
    J Invest Dermatol 2017 Apr 7. Epub 2017 Apr 7.
    Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
    Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances. CD155 is expressed in various types of cancer and this surface molecule on tumor cells functions either as a co-stimulatory molecule or a co-inhibitory molecule, depending on its receptor. CD226, a CD155 ligand, is mainly expressed on NK cells and CD8(+) T cells, playing important roles in NK cell-mediated cytotoxicity. Read More

    [Blastic plasmacytoid dendritic cell neoplasm with complete clinical remission with chemotherapy and central nervous system relapse: Report of one case].
    Rev Med Chil 2017 Jan;145(1):115-120
    Unidad de Anatomía Patológica, Hospital Dr. Guillermo Grant Benavente, Concepción, Chile.
    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that most commonly manifests as cutaneous lesions with or without bone marrow involvement and leukemic dissemination. The demonstration of tumor cells with the characteristic immunophenotype with expression of CD56, generally CD4 and dendritic cell antigens (CD123, cyTCL-1, HLA-DR), in the absence of myeloid or lymphoid lineage markers is required for the diagnosis. Responses to chemotherapy are initially satisfactory, with frequent systemic and central nervous system relapses. Read More

    Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma.
    J Dermatol 2017 Apr 9. Epub 2017 Apr 9.
    Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
    We retrospectively reviewed data pertaining to five patients with cutaneous T-cell lymphoma (CTCL) who had received hematopoietic stem cell transplantation (HSCT) between 2004 and 2015 at Kurume University Hospital, along with their clinical data until March 2016. For patients with advanced CTCL eligible for HSCT, autologous HSCT was performed when they responded well to chemotherapy, and allogeneic HSCT was selected for patients with advanced mycosis fungoides (MF)/Sézary syndrome (SS) and CTCL other than MF/SS with poor chemosensitivity. Two patients (primary cutaneous anaplastic large cell lymphoma and primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma) who responded well to chemotherapy received autologous HSCT: one patient was alive in partial remission and the other died due to therapy-related acute myeloid leukemia without disease relapse. Read More

    CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.
    J Immunol 2017 May 7;198(10):3897-3908. Epub 2017 Apr 7.
    Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan.
    CXCL17 is expressed in a variety of cancers and promotes tumor progression by recruiting myeloid-derived suppressor cells (MDSCs). MDSCs suppress tumor immunity by attracting regulatory T cells (Tregs) into tumor sites through CCL5. In this study, we examined the role of CXCL17 in skin disorders. Read More

    Renaissance of Low-Dose Radiotherapy Concepts for Cutaneous Lymphomas.
    Oncol Res Treat 2017 6;40(5):255-260. Epub 2017 Apr 6.
    Primary cutaneous B- and T-cell lymphomas are rare types of non-Hodgkin's lymphoma with a unique presentation. This can make it challenging for clinicians to manage these cases, and quite often the management mirrors that of other commonly seen lymphomas. This document summarizes how to manage primary cutaneous lymphoma with specific focus on the role of ultralow-dose radiation. Read More

    Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Case Series and Review of the Literature.
    Am J Dermatopathol 2017 May;39(5):374-383
    *Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY; †Department of Dermatology, University of Colorado Anschutz Medical College, Aurora, CO; and ‡Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY.
    Primary cutaneous follicular helper T-cell (Tfh) lymphoma is a recently described variant of peripheral T-cell lymphoma-not otherwise specified. This particular variant, usually presenting as a sudden onset of multiple plaques and nodules, is characterized by tumoral atypical T cells that express an array of Tfh markers, such as inducible T-cell costimulator, Bcl-6, CXCL13, PD-1, and CD10. The authors now present 3 patients whose known clinical skin findings are consistent with PTCL of Tfh origin (PTCL-Tfh). Read More

    RARα/RXR Synergism Potentiates Retinoid Responsiveness in Cutaneous T Cell Lymphoma Cell Lines.
    Exp Dermatol 2017 Mar 31. Epub 2017 Mar 31.
    Department of Biochemistry and Molecular Biology, The Brody School of Medicine, East Carolina University, Greenville, NC 27834.
    Retinoids, natural and synthetic derivatives of vitamin A, induce cellular changes by activating nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR). Although the ability of retinoids to govern gene expression is exploited clinically for cancer therapeutics, the full benefit of retinoid-based strategies is unrealized due to detrimental side effects. Delineating the receptors that prompt cellular outcomes is critical to advancing retinoid-based approaches. Read More

    European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
    Eur J Cancer 2017 May 31;77:57-74. Epub 2017 Mar 31.
    Department of Dermatology, Medical University of Vienna, Vienna, Austria.
    In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS has advanced, the staging system has been revised, new outcome data have been published and novel treatment options have been introduced. The purpose of the present document is to update the original recommendations bearing in mind that there are still only a limited number of controlled studies to support treatment decisions for MF/SS and that often treatment is determined by institutional experience and availability. Read More

    Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.
    Cancer Res Treat 2017 Mar 30. Epub 2017 Mar 30.
    Cancer Registration and Statistics branch, National Cancer Center, Goyang, Korea.
    Purpose: Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies.

    Materials And Methods: The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Read More

    Remission of subcutaneous panniculitis-like T-cell lymphoma in a pregnant woman after treatment with oral corticosteroids as monotherapy.
    JAAD Case Rep 2017 Mar 20;3(2):87-89. Epub 2017 Mar 20.
    Department of Dermatology, University of California at San Francisco, San Francisco, California; Department of Pathology, University of California at San Francisco, San Francisco, California.
    Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of cutaneous T-cell lymphoma characterized by neoplastic α/β T cells infiltrating subcutaneous tissues in a lobular pattern. Few data support the optimal treatment regimen for patients, given the rarity of this condition, and even fewer data describe treatment when diagnosed during pregnancy. We describe a case of SPTCL in a pregnant patient who achieved clinical remission after treatment with corticosteroid monotherapy. Read More

    1 OF 221